Pracinostat dihydrochloride 

Pracinostat dihydrochloride is a potent histone deacetylase (HDAC) inhibitor, with IC₅₀s of 40-140 nM, used for cancer research. Pracinostat dihydrochloride also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM^[1][4].

IC50: 40 nM (HDAC10), 43 nM (HDAC3), 47 nM (HDAC5), 49 nM (HDAC1), 56 nM (HDAC4), 70 nM (HDAC9), 93 nM (HDAC11), 96 nM (HDAC2), 137 nM (HDAC7), 140 nM (HDAC8), 1008 nM (HDAC6)^[1]

431.40

C₂₀H₃₂Cl₂N₄O₂

929016-98-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Novotny-Diermayr V, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010 Mar;9(3):642-52.  [Content Brief]

  [2]. Wang H, et al. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J Med Chem. 2011 Jul 14;54(13):4694-720.  [Content Brief]

  [3]. Novotny-Diermayr V, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2012 May;2(5):e69.  [Content Brief]

  [4]. Lechner S, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Aug;18(8):812-820.  [Content Brief]